LOS ANGELES & TORONTO--(BUSINESS WIRE)--June 7, 2006--Abraxis BioScience, Inc. (NASDAQ:ABBI - News): Abraxis BioScience, Inc. (NASDAQ:ABBI - News), an integrated, global biopharmaceutical company, today announced it has received approval for ABRAXANE(TM) for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound (nab) paclitaxel) from the Therapeutic Products Directorate of Health Canada under a Notice of Compliance for the treatment of metastatic breast cancer in Canada. Canada is the first major commercial market to grant an approval for ABRAXANE that includes first-line treatment of metastatic breast cancer. The company, through its Canadian affiliate of Abraxis Oncology, anticipates launching ABRAXANE late in the third quarter of 2006.
